Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St declines as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Bloom Energy shares fall on Oracle project halt
- Oppenheimer sees AI software winners as focus shifts to ROI
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
- Arm Holdings falls as CFO stock sale weighs on sentiment
Fulcrum Therapeutics Inc. (FULC) Misses Q2 EPS by 17c
August 11, 2022 7:14 AM EDTFulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q2 EPS of ($0.83), $0.17 worse than the analyst estimate of ($0.66). Revenue for the quarter came in at $1.88 million versus the consensus estimate of $2.96 million.
For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.
... More